ClinicalTrials.gg
Not yet recruitingNCT07386223HEAL-FHAUpdated Nov 12, 2026

Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA RCT)

An interventional study of Psychoeduation for FHA and Treatment as Usual (TAU) in Hypothalamic Amenorrhea, Functional, sponsored by Karolinska Institutet. Not yet recruiting at 1 site in Sweden. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn whether a 10-week digital psychoeducational health and lifestyle program can help women with functional hypothalamic amenorrhea (FHA) recover ovulatory menstrual cycles and endocrine function.

The main questions the study aims to answer are:

Does the program increase the proportion of women who have at least one spontaneous ovulatory menstrual cycle within 12 months? Does it improve hormonal markers of recovery of the hypothalamic-pituitary-ovarian axis, such as LH, FSH, estradiol and T3? Does it improve psychological well-being, stress and eating-related symptoms?

Researchers will compare the program with usual care to see whether the structured program leads to faster or more frequent recovery of menstrual and endocrine function than the care women typically receive today.

Participants will:

Be randomly assigned to the 10-week digital self-help program, delivered via the Swedish healthcare platform 1177 with one module per week (intervention group), or to usual care with a consultation with a gynecologist (comparison group); the comparison group is offered the program after the study Complete questionnaires and a structured diagnostic interview Provide blood samples to measure hormone levels at 3, 6, 9 and 12 months Contact the clinic if menstrual bleeding occurs, so that a blood sample can confirm ovulation Have a gynecological examination with ultrasound after 12 months to assess ovarian activity and endometrial thickness

This study builds on an ongoing feasibility study (NCT07589868) and will help determine whether the program is effective and should be offered more widely to women with FHA.

Read the detailed description

The study is a randomized, controlled trial with multicentre recruitment evaluating a 10-week digital psychoeducational health and lifestyle program with 12 months of follow-up in women with functional hypothalamic amenorrhea (FHA).

Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation and self-management skills. The program is compared with usual care to determine whether it leads to superior restoration of ovulatory menstrual cycles and endocrine function.

Study Aim To evaluate whether a 10-week digital psychoeducational program, compared with usual care, increases the proportion of women with FHA who recover spontaneous ovulatory menstrual cycles within 12 months.

Study Setting and Participants Seventy women aged 18-40 years with FHA (amenorrhea for ≥3 months and with a hypothalamic hormone profile: FSH \<10 IU/L, LH \<10 IU/L and estradiol \<200 pmol/L after exclusion of other causes of amenorrhea) are recruited through several gynecological clinics, with central coordination at Karolinska University Hospital. Individuals who meet exclusion criteria receive appropriate clinical information, standard care or referral to relevant healthcare services.

Intervention and Comparator The intervention is a 10-week self-help program delivered via the Swedish healthcare platform 1177 (Stöd och behandling) with one module per week and no therapist support. The comparison group receives usual care, including a consultation with a gynecologist with standard information about FHA, and is offered the program after the 12-month follow-up.

Sample Size In the only previous randomized trial (Berga et al. 2003), ovarian activity recovered in 87.5% of women receiving individual cognitive behavioural therapy compared with 25% with observation. Because small trials tend to overestimate effects, and because the present intervention is a digital self-help program with a stricter primary outcome, a difference of 60% versus 25% is assumed. With 80% power and two-sided α = 0.05, 30 evaluable participants per arm are required. Allowing for 15% attrition, 35 participants per arm (70 in total) will be randomized.

Study Design and Assessments Two-arm, parallel-group superiority trial with 1:1 allocation. Randomization is performed centrally by Karolinska Trial Alliance, stratified by FHA severity at baseline (severe: estradiol \<80 pmol/L and LH \<2.4 IU/L), with randomly varying block sizes. At the screening visit, all individuals complete the DIAMOND screening questions and the complete eating disorder module, with further modules after a positive screening question. Validated questionnaires (including EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6) and blood sampling (LH, FSH, estradiol, T3 and other hormones) are performed at baseline and at 3, 6, 9 and 12 months, with gynecological follow-up by video or in person. A gynecological examination with transvaginal ultrasound is performed at 12 months.

Data and Sample Collection Questionnaire data are collected electronically via REDCap. Findings from the feasibility study (NCT07589868) and the qualitative interview study inform the final protocol. Participants contact the clinic if menstrual bleeding occurs, and serum progesterone is measured on cycle day 21, counting the first day of bleeding as day 1, to assess ovulation.

Outcome Measures The primary outcome is the proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above [threshold] nmol/L) within 12 months. Secondary outcomes include time to first ovulatory cycle, number of spontaneous cycles, sustained recovery (≥3 consecutive cycles), change in LH, FSH, estradiol and T3, ultrasound signs of ovarian activity, psychological symptoms and well-being, and adverse events.

Statistical Analysis The primary analysis follows the intention-to-treat principle and compares the proportion with at least one spontaneous ovulatory cycle between groups, with the risk difference and 95% confidence interval and logistic regression adjusted for the stratification factor. Missing primary outcome data are handled with multiple imputation, with complete-case and worst-case sensitivity analyses. Secondary menstrual outcomes are analyzed with time-to-event methods and longitudinal outcomes with methods for repeated measurements. A detailed statistical analysis plan will be finalized before database lock.

Ethical Considerations Informed consent is obtained from all participants. The project is approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01, with amendments 2025-07620-02 and 2026-06250-02). The overall risk to participants is considered low, and adverse events are monitored throughout the study period.

02

Conditions studied

  • Hypothalamic Amenorrhea, Functional

Browse trials for

Keywords

  • psychoeduction
  • lifestyle change
  • menstrual restoration
  • amenorrhea
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 70 is above the median of 54 across 49 interventional studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Women aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist
  • amenorrhea for at least 3 months
  • a history compatible with functional hypothalamic amenorrhea
  • exclusion of other causes of amenorrhea
  • able to read and understand Swedish
  • access to an internet-enabled device and BankID
  • written .

Exclusion criteria:

  • Current anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion)
  • severe psychiatric comorbidity requiring other or more intensive care, including psychosis
  • insufficient Swedish proficiency
  • other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Psychoeducational Intervention

    Behavioral: HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months.

    Behavioral: Psychoeduation for FHA

  • Active comparator
    Treatment as Usual (TAU)

    Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months; access to the program offered after 12 months.

    Other: Treatment as Usual (TAU)

Interventions

  • BehavioralPsychoeduation for FHA

    HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months.

  • OtherTreatment as Usual (TAU)

    Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months.

06

What researchers measure

Primary outcomes

  1. Number of participants with return of spontaneous menstrual bleeding within 12 months from baseline.

    Proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above 13 nmol/L. \[Time frame: 12 months\].

    Time frame: Restoration of menstruation after 12 months of follow-up from baseline.

Secondary outcomes

  1. Time to spontaneous ovulatory cycles within 12 months from baseline.

    Time to first spontaneous ovulatory cycle; number of spontaneous cycles; sustained recovery (≥3 consecutive spontaneous cycles)

    Time frame: Baseline to 12 months

  2. Change in BMI within 12 months from baseline.

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: 6 and 12 months from baseline

  3. Change in serum luteinizing hormone (LH)

    Change from baseline in serum luteinizing hormone (LH).

    Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)

  4. Change in serum follicle-stimulating hormone (FSH)

    Change from baseline in serum FSH (IU/L).

    Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)

  5. Change in serum estradiol (E2)

    Change from baseline in serum estradiol (pmol/L), sensitive LC-MS/MS method.

    Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)

  6. Change in serum triiodothyronine (T3)

    Change from baseline in serum T3 (\[nmol/L or pmol/L, if free T3 - check with the laboratory\]).

    Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)

  7. Change in eating disorder symptoms (EDE-Q)

    Change from baseline in Eating Disorder Examination Questionnaire 6.0 global score (range 0-6; higher scores indicate more symptoms).

    Time frame: Baseline to 12 months

  8. Change in perceived stress (PSS-14)

    Change from baseline in Perceived Stress Scale total score (range 0-56; higher scores indicate more stress).

    Time frame: Baseline to 12 months

  9. Change in anxiety symptoms (GAD-7)

    Change from baseline in GAD-7 total score (range 0-21; higher scores indicate more anxiety).

    Time frame: Baseline to 12 months

  10. Change in depressive symptoms (PHQ-9)

    Change from baseline in PHQ-9 total score (range 0-27; higher scores indicate more depressive symptoms).

    Time frame: Baseline to 12 months

  11. Change in well-being (WHO-5)

    Change from baseline in WHO-5 percentage score (range 0-100; higher scores indicate better well-being).

    Time frame: Baseline to 12 months

07

Study locations

1 site
  • Kvinnohälsan Karolinska Universitetssjukhuset
    Stockholm, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — What data will be shared: De-identified individual participant data collected during the trial, including: Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments Other documents to be shared: Data dictionary describing all variables and coding used Study protocol and statistical analysis plan

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: When data will become available and for how long: Data will be available 6 months after publication of the primary trial results and will remain accessible for 5 years.

Access criteria: By what access criteria: Data will be available to qualified researchers for scientific purposes following submission of a research proposal and approval by the trial steering committee. Requests should be sent to the corresponding author or data custodian (contact information provided in the study publication).Data will be shared via a secure data repository

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2027; primary completion for Sep 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Feb 2026 → Sep 2027, primary completion Jan 2028 → Sep 2028 and completion Dec 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 4, 2026
StartEst.
Sep 1, 2027was Feb 2026
Primary completionEst.
Sep 1, 2028was Jan 2028
CompletionEst.
Dec 31, 2030was Dec 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 1, 2026→Sep 1, 2027
Nov 12, 2026
Primary completion
Jan 1, 2028→Sep 1, 2028
Nov 12, 2026
Study completion
Dec 31, 2028→Dec 31, 2030
Nov 12, 2026
Eligibility
Maximum age 42 Years→40 Years; Criteria largely rewritten (20 changes)
What changed in the criteria
  • AddedInclusion criteria:
  • AddedWomen aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist
  • Addedamenorrhea for at least 3 months
  • Addeda history compatible with functional hypothalamic amenorrhea
  • Addedexclusion of other causes of amenorrhea
  • Addedable to read and understand Swedish
  • Addedaccess to an internet-enabled device and BankID
  • Addedwritten informed consent.
  • AddedExclusion criteria:
  • AddedCurrent anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion)
  • Addedsevere psychiatric comorbidity requiring other or more intensive care, including psychosis
  • Addedinsufficient Swedish proficiency
  • Addedother causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
Inclusion criteria
  • Removedfemale
  • Removedaged 18-42 years
  • Removedfulfill criteria for diagnosis of functional hypothalamic amenorrhea (hypogonadotropic hypogonadism)
  • Removedbasic proficiency in Swedish
  • Removedaccess to a computer.
Exclusion criteria
  • RemovedLack of proficiency in language
  • Removedevere psychiatric co-morbidity e.g. psychosis or active eating disorders (anorexia nervosa).
Nov 12, 2026
Interventions
Added Behavioral: Psychoeduation for FHA; removed Behavioral: Psychoeducaction or treatment as usual
Nov 12, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedNumber of participants with return of spontaneous menstrual bleeding within 912 months from baseline.Time frame: Restoration of menstruation after 9 months of follow-up → Restoration of menstruation after 12 months of follow-up from baseline.
  • RemovedChange in serum FSH, LH, and estradiolTime frame: 12 months
Nov 12, 2026
Secondary outcomes
11 added
What changed in the outcomes
  • AddedTime to spontaneous ovulatory cycles within 12 months from baseline.Time frame: Baseline to 12 months
  • AddedChange in BMI within 12 months from baseline.Time frame: 6 and 12 months from baseline
  • AddedChange in serum luteinizing hormone (LH)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
  • AddedChange in serum follicle-stimulating hormone (FSH)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
  • AddedChange in serum estradiol (E2)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
  • AddedChange in serum triiodothyronine (T3)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
  • AddedChange in eating disorder symptoms (EDE-Q)Time frame: Baseline to 12 months
  • AddedChange in perceived stress (PSS-14)Time frame: Baseline to 12 months
  • AddedChange in anxiety symptoms (GAD-7)Time frame: Baseline to 12 months
  • AddedChange in depressive symptoms (PHQ-9)Time frame: Baseline to 12 months
  • AddedChange in well-being (WHO-5)Time frame: Baseline to 12 months
Nov 12, 2026
Title
Health and Lifestyle Support for Functional Hypothalamic Amenorrhea→Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA RCT)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Feb 1, 2026→Sep 1, 2027
    Primary completion Jan 1, 2028→Sep 1, 2028
    Study completion Dec 31, 2028→Dec 31, 2030
    Eligibility Maximum age 42 Years→40 Years; Criteria largely rewritten (20 changes)
    What changed in the criteria
    • AddedInclusion criteria:
    • AddedWomen aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist
    • Addedamenorrhea for at least 3 months
    • Addeda history compatible with functional hypothalamic amenorrhea
    • Addedexclusion of other causes of amenorrhea
    • Addedable to read and understand Swedish
    • Addedaccess to an internet-enabled device and BankID
    • Addedwritten informed consent.
    • AddedExclusion criteria:
    • AddedCurrent anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion)
    • Addedsevere psychiatric comorbidity requiring other or more intensive care, including psychosis
    • Addedinsufficient Swedish proficiency
    • Addedother causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
    Inclusion criteria
    • Removedfemale
    • Removedaged 18-42 years
    • Removedfulfill criteria for diagnosis of functional hypothalamic amenorrhea (hypogonadotropic hypogonadism)
    • Removedbasic proficiency in Swedish
    • Removedaccess to a computer.
    Exclusion criteria
    • RemovedLack of proficiency in language
    • Removedevere psychiatric co-morbidity e.g. psychosis or active eating disorders (anorexia nervosa).
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedNumber of participants with return of spontaneous menstrual bleeding within 912 months from baseline.Time frame: Restoration of menstruation after 9 months of follow-up → Restoration of menstruation after 12 months of follow-up from baseline.
    • RemovedChange in serum FSH, LH, and estradiolTime frame: 12 months
    Secondary outcomes 11 added
    What changed in the outcomes
    • AddedTime to spontaneous ovulatory cycles within 12 months from baseline.Time frame: Baseline to 12 months
    • AddedChange in BMI within 12 months from baseline.Time frame: 6 and 12 months from baseline
    • AddedChange in serum luteinizing hormone (LH)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
    • AddedChange in serum follicle-stimulating hormone (FSH)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
    • AddedChange in serum estradiol (E2)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
    • AddedChange in serum triiodothyronine (T3)Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
    • AddedChange in eating disorder symptoms (EDE-Q)Time frame: Baseline to 12 months
    • AddedChange in perceived stress (PSS-14)Time frame: Baseline to 12 months
    • AddedChange in anxiety symptoms (GAD-7)Time frame: Baseline to 12 months
    • AddedChange in depressive symptoms (PHQ-9)Time frame: Baseline to 12 months
    • AddedChange in well-being (WHO-5)Time frame: Baseline to 12 months
    Interventions Added Behavioral: Psychoeduation for FHA; removed Behavioral: Psychoeducaction or treatment as usual
    Title Health and Lifestyle Support for Functional Hypothalamic Amenorrhea→Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA RCT)
    + 4 other changes: index terms, verification date, responsible party and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07386223
Collaborators
Karolinska University Hospital, FoU Centrum, Landstinget Sörmland
Responsible party
Hedvig Engberg (Assistant Professor, MD, Karolinska Institutet) — Principal investigator
First posted
Feb 4, 2026
Start date
Sep 1, 2027 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Hedvig Engberg, MD PhD
Contact
hedvig.engberg@ki.se
+46 08 123 795 02
Anna Strandqvist, PhD
Contact
anna.strandqvist@ki.se
+46 08 123 779 69

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion